
Axon Enterprise AXON
$ 584.89
0.18%
Annual report 2024
added 05-07-2025
Axon Enterprise Cash Conversion Cycle 2011-2025 | AXON
Annual Cash Conversion Cycle Axon Enterprise
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.2 | 380 | 86.7 | 80.5 | 54.3 | 155 | 168 | 158 | 144 | 95.5 | 130 | 93.9 | 94.6 | 104 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 380 | 54.3 | 131 |
Quarterly Cash Conversion Cycle Axon Enterprise
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72 | - | - | 100 | 106 | 97.5 | - | 36 | 68 | 67.6 | - | 78.2 | 86.8 | 86.4 | - | 88.1 | 113 | 61.4 | - | 23.4 | 25.3 | 30.7 | - | 43.3 | 47 | 68.9 | - | 83.1 | 98.9 | 91 | - | 86.9 | 103 | 79.7 | - | 39.8 | 48.1 | 58.4 | - | 62.1 | 69.5 | 50.7 | - | 55.9 | 83.7 | 62.3 | - | 82.7 | 90.2 | 84.6 | - | 44.1 | 50.7 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 113 | 23.4 | 69.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aptevo Therapeutics
APVO
|
-47.4 | $ 0.55 | -9.98 % | $ 152 K | ||
|
Aclaris Therapeutics
ACRS
|
-881 | $ 3.02 | -0.33 % | $ 233 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
12 | $ 1.17 | 2.63 % | $ 6.38 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | ||
|
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 27.05 | -0.26 % | $ 1.31 B | ||
|
Catalyst Biosciences
CBIO
|
391 | $ 12.53 | 1.46 % | $ 825 M | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | ||
|
Anika Therapeutics
ANIK
|
270 | $ 9.56 | 0.1 % | $ 140 M | ||
|
Certara
CERT
|
78.4 | $ 8.81 | -0.9 % | $ 1.41 B | ||
|
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | ||
|
Cellectis S.A.
CLLS
|
-839 | $ 5.06 | 6.53 % | $ 116 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.46 | 0.2 % | $ 15.4 M | ||
|
AstraZeneca PLC
AZN
|
-58 | $ 92.58 | -0.35 % | $ 96.9 B | ||
|
ChromaDex Corporation
CDXC
|
23.8 | - | -0.88 % | $ 598 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | ||
|
Celldex Therapeutics
CLDX
|
-6.08 K | $ 26.26 | -0.53 % | $ 1.69 M |